References

10.1101/gad.334516.119

10.1101/gad.334516.119 · External reference

The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review

10.1186/s13578-020-00390-7 · 2020 · External reference

PARP inhibitor resistance: the underlying mechanisms and clinical implications

10.1186/s12943-020-01227-0 · 2020 · External reference

10.1158/2159-8290.cd-15-0714

10.1158/2159-8290.cd-15-0714 · External reference

Mapping genetic interactions in cancer: a road to rational combination therapies

10.1186/s13073-019-0680-4 · 2019 · External reference

10.1126/sciadv.aaz3221

10.1126/sciadv.aaz3221 · External reference

A landscape of synthetic viable interactions in cancer

2018 · External reference

10.1016/j.omtn.2019.07.003

10.1016/j.omtn.2019.07.003 · External reference

10.1038/nmeth.4225

10.1038/nmeth.4225 · External reference

10.1016/j.cell.2017.01.013

10.1016/j.cell.2017.01.013 · External reference

10.1038/nmeth.1581

10.1038/nmeth.1581 · External reference

10.1016/s1470-2045(18)30111-6

10.1016/s1470-2045(18)30111-6 · External reference

10.1038/nature06548

10.1038/nature06548 · External reference

Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer

10.1016/j.ygyno.2016.01.004 · 2016 · External reference

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo

10.1182/blood-2010-01-265769 · 2010 · External reference

ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition

10.1186/1756-9966-32-95 · 2013 · External reference

10.1158/1078-0432.ccr-15-2477

10.1158/1078-0432.ccr-15-2477 · External reference

Zona occludens proteins modulate podosome formation and function

10.1096/fj.10-155598 · 2011 · External reference

10.1016/j.celrep.2018.03.093

10.1016/j.celrep.2018.03.093 · External reference

10.1038/cr.2012.82

10.1038/cr.2012.82 · External reference

Unresolved reference

2009 · External reference

10.1016/j.ceb.2009.01.028

10.1016/j.ceb.2009.01.028 · External reference

Adhesion molecules in tumor metastasis

1993 · External reference

Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy

10.2147/dddt.s82035 · 2015 · External reference

Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro

10.1096/fj.09-140491 · 2010 · External reference

10.1056/nejmoa1911361

10.1056/nejmoa1911361 · External reference

The consequences of Rad51 overexpression for normal and tumor cells

10.1016/j.dnarep.2007.12.008 · 2008 · External reference

10.1101/cshperspect.a016600

10.1101/cshperspect.a016600 · External reference

10.1038/ng.3984

10.1038/ng.3984 · External reference

10.1038/s41586-019-1103-9

10.1038/s41586-019-1103-9 · External reference

10.1016/j.cell.2017.06.010

10.1016/j.cell.2017.06.010 · External reference

Contribution of common genetic variants to familial aggregation of disease and implications for sequencing studies

10.1371/journal.pgen.1008490 · 2019 · External reference

10.1038/nature11005

10.1038/nature11005 · External reference

10.1186/gb-2011-12-4-r41

10.1186/gb-2011-12-4-r41 · External reference

Identification of putative target genes for amplification within 11q13.2 and 3q27.1 in esophageal squamous cell carcinoma

10.1007/s12094-013-1124-z · 2014 · External reference

Integrating multi-omics data to dissect mechanisms of DNA repair dysregulation in breast cancer

10.1038/srep34000 · 2016 · External reference

A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy

10.1093/jnci/djs177 · 2012 · External reference

10.1093/nar/gkw1092

10.1093/nar/gkw1092 · External reference

10.1093/nar/gkq1039

10.1093/nar/gkq1039 · External reference

10.1093/nar/gkz337

10.1093/nar/gkz337 · External reference